{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:26:01Z","timestamp":1790616361721,"version":"4.1.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T00:00:00Z","timestamp":1553558400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s00280-019-03796-4","type":"journal-article","created":{"date-parts":[[2019,3,26]],"date-time":"2019-03-26T18:03:38Z","timestamp":1553623418000},"page":"1057-1063","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["First-in-human study to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of the anti-CD27L antibody-drug conjugate AMG 172 in patients with relapsed\/refractory renal cell carcinoma"],"prefix":"10.1007","volume":"83","author":[{"given":"Christophe","family":"Massard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00fcrgen","family":"Krauss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert Craig","family":"Lockhart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Rasmussen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vijay V.","family":"Upreti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonal","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gataree","family":"Ngarmchamnanrith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haby","family":"Henary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,3,26]]},"reference":[{"issue":"6","key":"3796_CR1","doi-asserted-by":"publisher","first-page":"804","DOI":"10.6004\/jnccn.2017.0100","volume":"15","author":"RJ Motzer","year":"2017","unstructured":"Motzer RJ, Jonasch E, Agarwal N, Bhayani S, Bro WP, Chang SS, Choueiri TK, Costello BA, Derweesh IH, Fishman M, Gallagher TH, Gore JL, Hancock SL, Harrison MR, Kim W, Kyriakopoulos C, LaGrange C, Lam ET, Lau C, Michaelson MD, Olencki T, Pierorazio PM, Plimack ER, Redman BG, Shuch B, Somer B, Sonpavde G, Sosman J, Dwyer M, Kumar R (2017) Kidney cancer, version 2.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15(6):804\u2013834. \n                    https:\/\/doi.org\/10.6004\/jnccn.2017.0100","journal-title":"J Natl Compr Canc Netw"},{"issue":"3","key":"3796_CR2","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1016\/j.eururo.2018.03.036","volume":"74","author":"CJD Wallis","year":"2018","unstructured":"Wallis CJD, Klaassen Z, Bhindi B, Ye XY, Chandrasekar T, Farrell AM, Goldberg H, Boorjian SA, Leibovich B, Kulkarni GS, Shah PS, Bjarnason GA, Heng DYC, Satkunasivam R, Finelli A (2018) First-line systemic therapy for metastatic renal cell carcinoma: a systematic review and network meta-analysis. Eur Urol 74(3):309\u2013321. \n                    https:\/\/doi.org\/10.1016\/j.eururo.2018.03.036","journal-title":"Eur Urol"},{"issue":"3","key":"3796_CR3","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1016\/0092-8674(93)90133-B","volume":"73","author":"RG Goodwin","year":"1993","unstructured":"Goodwin RG, Alderson MR, Smith CA, Armitage RJ, VandenBos T, Jerzy R, Tough TW, Schoenborn MA, Davis-Smith T, Hennen K, Falk B, Cosman D, Baker E, Sutherland GR, Grabstein KH, Farrah T, Giri JG, Beckmann MP (1993) Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73(3):447\u2013456. \n                    https:\/\/doi.org\/10.1016\/0092-8674(93)90133-B","journal-title":"Cell"},{"issue":"2","key":"3796_CR4","doi-asserted-by":"publisher","first-page":"710","DOI":"10.4049\/jimmunol.174.2.710","volume":"174","author":"TN Bullock","year":"2005","unstructured":"Bullock TN, Yagita H (2005) Induction of CD70 on dendritic cells through CD40 or TLR stimulation contributes to the development of CD8+ T cell responses in the absence of CD4+ T cells. J Immunol 174(2):710\u2013717. \n                    https:\/\/doi.org\/10.4049\/jimmunol.174.2.710","journal-title":"J Immunol"},{"issue":"3","key":"3796_CR5","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1093\/intimm\/6.3.477","volume":"6","author":"RQ Hintzen","year":"1994","unstructured":"Hintzen RQ, Lens SM, Koopman G, Pals ST, Spits H, van Lier RA (1994) CD70 represents the human ligand for CD27. Int Immunol 6(3):477\u2013480. \n                    https:\/\/doi.org\/10.1093\/intimm\/6.3.477","journal-title":"Int Immunol"},{"issue":"3","key":"3796_CR6","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1002\/ijc.10207","volume":"98","author":"J Held-Feindt","year":"2002","unstructured":"Held-Feindt J, Mentlein R (2002) CD70\/CD27 ligand, a member of the TNF family, is expressed in human brain tumors. Int J Cancer 98(3):352\u2013356. \n                    https:\/\/doi.org\/10.1002\/ijc.10207","journal-title":"Int J Cancer"},{"issue":"12","key":"3796_CR7","doi-asserted-by":"crossref","first-page":"3556","DOI":"10.1182\/blood.V85.12.3556.bloodjournal85123556","volume":"85","author":"EA Ranheim","year":"1995","unstructured":"Ranheim EA, Cantwell MJ, Kipps TJ (1995) Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 85(12):3556\u20133565","journal-title":"Blood"},{"issue":"5","key":"3796_CR8","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1097\/00000478-200005000-00014","volume":"24","author":"T Hishima","year":"2000","unstructured":"Hishima T, Fukayama M, Hayashi Y, Fujii T, Ooba T, Funata N, Koike M (2000) CD70 expression in thymic carcinoma. Am J Surg Pathol 24(5):742\u2013746","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"3796_CR9","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1097\/01.ju.0000158121.49085.ba","volume":"173","author":"K Junker","year":"2005","unstructured":"Junker K, Hindermann W, von Eggeling F, Diegmann J, Haessler K, Schubert J (2005) CD70: a new tumor specific biomarker for renal cell carcinoma. J Urol 173(6):2150\u20132153. \n                    https:\/\/doi.org\/10.1097\/01.ju.0000158121.49085.ba","journal-title":"J Urol"},{"issue":"1","key":"3796_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/bjc.2015.412","volume":"114","author":"C Pich","year":"2016","unstructured":"Pich C, Sarrabayrouse G, Teiti I, Mariam\u00e9 B, Rochaix P, Lamant L, Favre G, Maisongrosse V, Tilkin-Mariam\u00e9 AF (2016) Melanoma-expressed CD70 is involved in invasion and metastasis. Br J Cancer 114(1):63\u201370. \n                    https:\/\/doi.org\/10.1038\/bjc.2015.412","journal-title":"Br J Cancer"},{"issue":"4","key":"3796_CR11","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1158\/0008-5472.CAN-05-2883","volume":"66","author":"CL Law","year":"2006","unstructured":"Law CL, Gordon KA, Toki BE, Yamane AK, Hering MA, Cerveny CG, Petroziello JM, Ryan MC, Smith L, Simon R, Sauter G, Oflazoglu E, Doronina SO, Meyer DL, Francisco JA, Carter P, Senter PD, Copland JA, Wood CG, Wahl AF (2006) Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates. Cancer Res 66(4):2328\u20132337. \n                    https:\/\/doi.org\/10.1158\/0008-5472.CAN-05-2883","journal-title":"Cancer Res"},{"issue":"9","key":"3796_CR12","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1016\/j.humpath.2011.10.014","volume":"43","author":"LB Jilaveanu","year":"2012","unstructured":"Jilaveanu LB, Sznol J, Aziz SA, Duchen D, Kluger HM, Camp RL (2012) CD70 expression patterns in renal cell carcinoma. Hum Pathol 43(9):1394\u20131399. \n                    https:\/\/doi.org\/10.1016\/j.humpath.2011.10.014","journal-title":"Hum Pathol"},{"issue":"3","key":"3796_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1038\/sj.bjc.6603222","volume":"95","author":"PJ Adam","year":"2006","unstructured":"Adam PJ, Terrett JA, Steers G, Stockwin L, Loader JA, Fletcher GC, Lu LS, Leach BI, Mason S, Stamps AC, Boyd RS, Pezzella F, Gatter KC, Harris AL (2006) CD70 (TNFSF7) is expressed at high prevalence in renal cell carcinomas and is rapidly internalised on antibody binding. Br J Cancer 95(3):298\u2013306. \n                    https:\/\/doi.org\/10.1038\/sj.bjc.6603222","journal-title":"Br J Cancer"},{"issue":"1","key":"3796_CR14","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1177\/009286150303700108","volume":"37","author":"Y Zhou","year":"2003","unstructured":"Zhou Y, Whitehead J (2003) Practical implementation of Bayesian dose-escalation procedures. Drug Inf J 37(1):45\u201359. \n                    https:\/\/doi.org\/10.1177\/009286150303700108","journal-title":"Drug Inf J"},{"issue":"3","key":"3796_CR15","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1080\/10543409808835252","volume":"8","author":"J Whitehead","year":"1998","unstructured":"Whitehead J, Williamson D (1998) Bayesian decision procedures based on logistic regression models for dose-finding studies. J Biopharm Stat 8(3):445\u2013467. \n                    https:\/\/doi.org\/10.1080\/10543409808835252","journal-title":"J Biopharm Stat"},{"key":"3796_CR16","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/978-1-62703-050-2_16","volume":"929","author":"J Gabrielsson","year":"2012","unstructured":"Gabrielsson J, Weiner D (2012) Non-compartmental analysis. Methods Mol Biol 929:377\u2013389. \n                    https:\/\/doi.org\/10.1007\/978-1-62703-050-2_16","journal-title":"Methods Mol Biol"},{"key":"3796_CR17","unstructured":"Chow V, Fanslow W, Hinkle B, Patel S, Upreti V, Retter M, Hill J, Paccaly A (2014) Translating preclinical toxicology, PK and PK\/PD for tumor volume (xenografts) to support AMG 172 first in human study. Poster T2048. Presented at the AAPS National Biotechnology Conference, San Diego, CA"},{"issue":"4","key":"3796_CR18","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1083\/jcb.201006102","volume":"191","author":"JN Thon","year":"2010","unstructured":"Thon JN, Montalvo A, Patel-Hett S, Devine MT, Richardson JL, Ehrlicher A, Larson MK, Hoffmeister K, Hartwig JH, Italiano JE Jr (2010) Cytoskeletal mechanics of proplatelet maturation and platelet release. J Cell Biol 191(4):861\u2013874. \n                    https:\/\/doi.org\/10.1083\/jcb.201006102","journal-title":"J Cell Biol"},{"issue":"8","key":"3796_CR19","doi-asserted-by":"publisher","first-page":"1989","DOI":"10.1158\/1078-0432.CCR-15-1542","volume":"22","author":"F Do\u00f1ate","year":"2016","unstructured":"Do\u00f1ate F, Raitano A, Morrison K, An Z, Capo L, Avi\u00f1a H, Karki S, Morrison K, Yang P, Ou J, Moriya R, Shostak Y, Malik F, Nadell R, Liu W, Satpayev D, Atkinson J, Joseph IB, Pereira DS, Challita-Eid PM, Stover DR (2016) AGS16F is a novel antibody drug conjugate directed against ENPP3 for the treatment of renal cell carcinoma. Clin Cancer Res 22(8):1989\u20131999. \n                    https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1542","journal-title":"Clin Cancer Res"},{"issue":"6","key":"3796_CR20","doi-asserted-by":"publisher","first-page":"1246","DOI":"10.1007\/s10637-014-0151-0","volume":"32","author":"NM Tannir","year":"2014","unstructured":"Tannir NM, Forero-Torres A, Ramchandren R, Pal SK, Ansell SM, Infante JR, de Vos S, Hamlin PA, Kim SK, Whiting NC, Gartner EM, Zhao B, Thompson JA (2014) Phase I dose-escalation study of SGN-75 in patients with CD70-positive relapsed\/refractory non-Hodgkin lymphoma or metastatic renal cell carcinoma. Invest New Drugs 32(6):1246\u20131257. \n                    https:\/\/doi.org\/10.1007\/s10637-014-0151-0","journal-title":"Invest New Drugs"},{"issue":"7","key":"3796_CR21","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.1021\/bc400217g","volume":"24","author":"SC Jeffrey","year":"2013","unstructured":"Jeffrey SC, Burke PJ, Lyon RP, Meyer DW, Sussman D, Anderson M, Hunter JH, Leiske CI, Miyamoto JB, Nicholas ND, Okeley NM, Sanderson RJ, Stone IJ, Zeng W, Gregson SJ, Masterson L, Tiberghien AC, Howard PW, Thurston DE, Law CL, Senter PD (2013) A potent anti-CD70 antibody-drug conjugate combining a dimeric pyrrolobenzodiazepine drug with site-specific conjugation technology. Bioconjug Chem 24(7):1256\u20131263. \n                    https:\/\/doi.org\/10.1021\/bc400217g","journal-title":"Bioconjug Chem"},{"issue":"12","key":"3796_CR22","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1158\/1535-7163.MCT-16-0393","volume":"15","author":"LJ Thomas","year":"2016","unstructured":"Thomas LJ, Vitale L, O\u2019Neill T, Dolnick RY, Wallace PK, Minderman H, Gergel LE, Forsberg EM, Boyer JM, Storey JR, Pilsmaker CD, Hammond RA, Widger J, Sundarapandiyan K, Crocker A, Marsh HC Jr, Keler T (2016) Development of a novel antibody-drug conjugate for the potential treatment of ovarian, lung, and renal cell carcinoma expressing TIM-1. Mol Cancer Ther 15(12):2946\u20132954. \n                    https:\/\/doi.org\/10.1158\/1535-7163.MCT-16-0393","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"3796_CR23","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s00280-015-2909-2","volume":"77","author":"TK Owonikoko","year":"2016","unstructured":"Owonikoko TK, Hussain A, Stadler WM, Smith DC, Kluger H, Molina AM, Gulati P, Shah A, Ahlers CM, Cardarelli PM, Cohen LJ (2016) First-in-human multicenter phase I study of BMS-936561 (MDX-1203), an antibody-drug conjugate targeting CD70. Cancer Chemother Pharmacol 77(1):155\u2013162. \n                    https:\/\/doi.org\/10.1007\/s00280-015-2909-2","journal-title":"Cancer Chemother Pharmacol"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03796-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03796-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,25]],"date-time":"2020-03-25T00:09:00Z","timestamp":1585094940000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03796-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,26]]},"references-count":23,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["3796"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03796-4","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,26]]},"assertion":[{"value":"27 November 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 February 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 March 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"CM has received fees for advisory boards, as a speaker or an investigator from Amgen, Astellas, AstraZeneca, Bayer, Celgene, Genentech, Ipsen, Janssen, Lilly, Novartis, Pfizer, Roche, Sanofi, and Orion. J-CS has received research funding from Amgen, and consultancy fees from AstraZeneca, Bristol-Meyers Squibb, Roche, Sanofi, Pierre Fabre, and Servier. MG has a clinical trials selection process pending. ER, VVU, and GN are employees of Amgen and holders of Amgen stocks. SP was an employee of Amgen from 2005 to 2015. HH is an employee of Amgen. JK and ACL have nothing to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}